Sai Life Sciences, one of India’s fastest growing contract development and manufacturing organisations, is to establish its first European hub at Alderley Park, part of the Bruntwood SciTech network.
The business, which works globally with innovative biotech and pharma companies to accelerate the discovery, development and manufacture of complex small molecules, aims to support the launch of 25 new medicines by 2025.
It already works with seven of the world’s top 10 large pharma companies, as well as several small- and mid-sized pharma and biotech companies, and will now join a community of more than 200 science and technology businesses at the UK’s largest single site life science campus in a bid to support this goal.
Sai Life Sciences’ lab at Alderley Park will enable seamless integration between the rest of the company’s service offerings across the US and India, and which span the drug discovery and development continuum from biology, medicinal chemistry, DMPK and toxicology, through to process development and commercial scale manufacturing.
Andrew Kennedy, vice president and Manchester site head at Sai Life Sciences, said: “Alderley Park’s world-class facilities make it the perfect place for us to set-up a centre of excellence for small molecule API process development that will have a positive and lasting impact on the future of healthcare.
“To achieve our goal of supporting the development of 25 new medicines by 2025, it’s important that we’re part of a community that is dedicated to nurturing science and innovation, and with access to some of the finest pharmaceutical talent, excellent travel links and a broad range of businesses across the sector, we’re looking forward to establishing our first European base here at Alderley Park.”
